Sumatriptan, GR43175 (3-[2-(dimethylamino)ethyl]-
N-methyl-1H-indole-5-methane sulfonamide), is a selective 5-hydroxytryptamine (5HT1) receptor agonist effective in the acute treatment of migraine,1,2 possibly by reversal of intracranial arterial dilatation. 3 The 5HT, receptor may be further subdivided into 5HT, a-d subtypes. There is some evidence that sumatriptan is a selective 5HTld receptor agonist. [4] [5] [6] In isolated vascular preparations, it has been shown to cause selective constriction of rabbit,7 dog, and primate basilar arteries8 and dog saphenous vein. 9 In anesthetized intact animals, it caused selective vasoconstriction of feline and canine carotid arterial circulations, with no effect on extracranial vascular beds. 10'11 Human isolated basilar artery rings constricted in response to sumatriptan,12 as did normal and atherosclerotic human epicardial coronary artery rings from explanted hearts.13"4 In early clinical trials, transient increases in systolic and diastolic arterial blood pressures were seen after administration of sumatriptan, but this was not a consistent finding in all subjects.",2 strated noninvasively in humans after sumatriptan. 15 These studies suggested that sumatriptan causes vasoconstriction of various vascular beds in humans and that in humans, 5HT, receptors may not be confined to the cranial circulation, unlike other species.
The object of this study was therefore to determine the effects on central hemodynamics and coronary vascular tone of sumatriptan given in the standard 6-mg subcutaneous dose used in migraine.
Methods

Patient Group
Ten patients, six men and four women (mean age, 49+11 years), were studied during coronary arteriography being performed for diagnostic purposes. All vasoactive therapy other than sublingual glyceryl trinitrate was discontinued 24 hours before the study.
Exclusion criteria included women of childbearing potential, myocardial infarction within 3 months, unstable angina, cardiac arrhythmias, and hypertension (diastolic blood pressure .95 mm Hg). Because this drug had the potential to cause vasoconstriction, patients found to have coronary artery stenosis of .50% during diagnostic angiography were not entered.
The study was approved by the Ethics Committee of Stobhill General Hospital. Each patient was issued an appropriate information sheet, and written informed consent was obtained.
Central Hemodynamic Monitoring
Routine left ventricular angiography and selective coronary arteriography were performed by the conventional Judkins technique.
After the diagnostic procedure, the Judkins catheter was retained in the aorta to measure systemic arterial systolic and diastolic blood pressures. A 7F balloon flotation catheter was positioned in the pulmonary artery and used to measure pulmonary artery systolic, diastolic, and occluded wedge pressures. Hard copies of systemic and pulmonary arterial pressure tracings were obtained at baseline and at 5-minute intervals until repeated measurements were within 5% to confirm reproducibility. Thereafter, the pressures were measured at 5-minute intervals for a total of 40 minutes after injection of sumatriptan. Heart rate was measured from a continuously monitored ECG, and hard-copy ECGs were obtained at 5-minute intervals. Cardiac output was measured by the thermodilution technique, a mean value of at least three measurements at each time point. The total systemic vascular resistance and the total pulmonary vascular resistance were calculated at baseline, 10 minutes, and 30 minutes after injection.
Drug Administration
After baseline measurements, sumatriptan (6 mg s.c.) was injected into the deltoid region of the right arm. Blood sampling to determine sumatriptan concentration was performed at 10 and 30 minutes after injection.
Quantitative Coronary Angiography
Seven left and three right coronary arteries were studied. After visualization of the coronary artery system in the standard views, a projection was chosen that allowed simultaneous visualization of the coronary artery system and the diagnostic 7F catheter that was used as the reference of measurement. Serial angiograms were obtained with a Siemens angioscope C arm. The x-ray tube-to-patient distance was fixed to maintain identical magnification and to avoid parallax error. Nonionic contrast medium (4-7 ml) (Niopam, Merck Products) was injected by hand into the coronary artery under study. Hard-copy end-diastolic frames were processed from the third or fourth cardiac cycles for analysis of coronary artery dimensions with a 512x512 matrix in mask mode using a Siemens on-line Digitron II software DSA system at baseline and at 10 and 30 minutes after injection. Several corresponding segments were identified along the length of the artery on each of the hard-copy films. Two blinded observers used digital calipers (Summagraphics digitizer) to measure coronary artery diameter at these corresponding segments. The external diameter of the catheter (7F; nominal value, 2.33 mm) was measured to convert the coronary artery diameter to an absolute value. The mean absolute coronary diameter was calculated for each time point.
Reproducibility Study
The reproducibility of the methodology to measure coronary artery dimensions was assessed in eight more patients (five men, three women; mean age, 60.5+±5.6 years) undergoing diagnostic coronary arteriography. We demonstrated a vasoconstrictor effect of sumatriptan on epicardial coronary arteries by serial quantitative digital subtraction angiography. The observed 16% reduction in coronary artery diameter was not accompanied by clinical symptoms or ECG evidence of myocardial ischemia. The rise in systemic arterial diastolic pressure will lead to an increase in coronary artery perfusion pressure. This may offset the reduction in coronary artery blood flow caused by the reduction in coronary artery diameter. Further experiments that measure coronary artery blood flow directly are required to confirm this.
In vitro, the vasoconstrictive effects of serotonin in normal and atherosclerotic coronary artery rings have been shown to be predominantly 5HT2-receptor mediated.13'14 However, a small ketanserin-resistant contraction was produced by sumatriptan and therefore attributed to 5HT, receptor activation. Although the magnitude of this 5HT1-mediated contraction is small compared with the 5HT2 response, it could become functionally significant in vivo in the presence of severe coronary artery stenosis. The development of selective 5HT1 antagonists may be of therapeutic value.
The plasma levels of sumatriptan obtained at 10 and 
